Home
Drugs
Ajovy

Ajovy

Drug

Also known as: Ajovy, AJOVY

Drug Profile

Ajovy (fremanezumab-vfrm) is a calcitonin gene-related peptide antagonist used for preventive migraine treatment. Current U.S. labeling includes adults and pediatric episodic migraine patients aged 6 to 17 years who weigh at least 45 kg. It is given by subcutaneous injection with monthly or quarterly adult dosing options.

Drug Class: Calcitonin gene-related peptide (CGRP) antagonist monoclonal antibody
Approval Status: FDA approved (initial U.S. approval 2018; labeling revised August 2025)
Mechanism of Action: Fremanezumab binds to calcitonin gene-related peptide ligand and blocks CGRP receptor signaling

Brand Names

AJOVY

Indications

\Preventive treatment of migraine in adults\
\Preventive treatment of episodic migraine in pediatric patients aged 6 to 17 years weighing 45 kg or more\

Related News

Teva Reports Positive Long-Term IBD Data for Duvakitug, FDA Accepts TEV-749 Application

Mar 01, 2026

Teva and Sanofi reported durable 44-week efficacy for duvakitug in inflammatory bowel disease, while the FDA accepted Teva's application for TEV-749, a once-monthly olanzapine injection for schizophrenia.

FDA Accepts Teva's Application for Once-Monthly Schizophrenia Injectable

Feb 20, 2026

The FDA has accepted Teva Pharmaceutical's New Drug Application for TEV-'749, a once-monthly subcutaneous olanzapine extended-release injectable suspension for treating schizophrenia in adults, supported by Phase 3 SOLARIS trial data.